Integrated Filing — IndAS


General information about company
Scrip Code 500087
NSE Symbol CIPLA
MSEI Symbol NOTLISTED
ISIN INE059A01026
Name of company CIPLA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 13-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 13-May-2025   11:00:00
End date and time of board meeting 13-May-2025   13:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-01-28
Indicate Company website link for updated RPT policy of the Company https://www.cipla.com/sites/default/files/2025-03/Policy-on-Related-Party-Transaction_clean.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 47978900000 190448500000
Other income 2933700000 9847200000
Total income 50912600000 200295700000
2 Expenses
(a) Cost of materials consumed 9236000000 36428400000
(b) Purchases of stock-in-trade 4647600000 20567500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -67500000 -2298700000
(d) Employee benefit expense 7849300000 30548700000
(e) Finance costs 34900000 151100000
(f) Depreciation, depletion and amortisation expense 1477000000 5738900000
(f) Other Expenses
1 Other Expenses 13126400000 47418200000
Total other expenses 13126400000 47418200000
Total expenses 36303700000 138554100000
3 Total profit before exceptional items and tax 14608900000 61741600000
4 Exceptional items 2946600000 2946600000
5 Total profit before tax 17555500000 64688200000
6 Tax expense
7 Current tax 3327100000 13603200000
8 Deferred tax -625600000 -491500000
9 Total tax expenses 2701500000 13111700000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 14854000000 51576500000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 14854000000 51576500000
17 Other comprehensive income net of taxes 393700000 -99800000
18 Total Comprehensive Income for the period 15247700000 51476700000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1615200000 1615200000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 319377200000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 18.39 63.87
Diluted earnings (loss) per share from continuing operations 18.38 63.82
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 18.39 63.87
Diluted earnings (loss) per share from continuing and discontinued operations 18.38 63.82
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 35076400000
Capital work-in-progress 5231100000
Investment property 1128700000
Goodwill 0
Other intangible assets 2571200000
Intangible assets under development 1152900000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 105016800000
Trade receivables, non-current 0
Loans, non-current 9755400000
Other non-current financial assets 3759700000
Total non-current financial assets 118531900000
Deferred tax assets (net) 198800000
Other non-current assets 7678500000
Total non-current assets 171569500000
2 Current assets
Inventories 36071200000
Current financial asset
Current investments 68493100000
Trade receivables, current 38599900000
Cash and cash equivalents 827400000
Bank balance other than cash and cash equivalents 1957100000
Loans, current 2138700000
Other current financial assets 28853700000
Total current financial assets 140869900000
Current tax assets (net) 0
Other current assets 6751100000
Total current assets 183692200000
3 Non-current assets classified as held for sale 395500000
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 355657200000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1615200000
Other equity 319377200000
Total equity attributable to owners of parent 320992400000
Non controlling interest
Total equity 320992400000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 1217100000
Total non-current financial liabilities 1217100000
Provisions, non-current 1091200000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 522300000
Total non-current liabilities 2830600000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2184000000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 16653100000
Total Trade payable 18837100000
Other current financial liabilities 2663100000
Total current financial liabilities 21500200000
Other current liabilities 2005400000
Provisions, current 7772500000
Current tax liabilities (Net) 556100000
Deferred government grants, Current 0
Total current liabilities 31834200000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 34664800000
Total equity and liabilites 355657200000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss_ Continuing operations -64300000 -168200000
2 Items that will not be reclassified to profit or loss_Discontinuing operations 0 0
Total Amount of items that will not be reclassified to profit and loss -64300000 -168200000
2 Income tax relating to items that will not be reclassified to profit or loss -16300000 -42400000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 590200000 34700000
Total Amount of items that will be reclassified to profit and loss 590200000 34700000
4 Income tax relating to items that will be reclassified to profit or loss 148500000 8700000
5 Total Other comprehensive income 393700000 -99800000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 64688200000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 151100000
Adjustments for decrease (increase) in inventories -3528500000
Adjustments for decrease (increase) in trade receivables, current -11243900000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 0
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 2480800000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 5738900000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -14600000
Adjustments for dividend income 0
Adjustments for interest income 3996500000
Adjustments for share-based payments 271500000
Adjustments for fair value losses (gains) -2370200000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -1570100000
Other adjustments to reconcile profit (loss) -2946600000
Other adjustments for non-cash items -73900000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -17102000000
Net cash flows from (used in) operations 47586200000
Dividends received -992700000
Interest paid 0
Interest received 0
Income taxes paid (refund) 13583600000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 33009900000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 8828000000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 60000000
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 237200000
Purchase of property, plant and equipment 5710600000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 1576200000
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 178300000
Cash advances and loans made to other parties 4933700000
Cash receipts from repayment of advances and loans made to other parties 15002700000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 992700000
Interest received 4151300000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -22182400000
Net cash flows from (used in) investing activities -23085300000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 500000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 147600000
Dividends paid 10498300000
Interest paid 93900000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -10739300000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -814700000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents -3100000
Net increase (decrease) in cash and cash equivalents -817800000
Cash and cash equivalents cash flow statement at beginning of period 1645200000
Cash and cash equivalents cash flow statement at end of period 827400000







Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok & Co LLP Yes 31-May-2025


Financial details
Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail
Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Cipla Limited AMP Energy Green Eleven Private Limited Associate Any other transaction Electricity charges paid 120000000 Approved 42700000 0 0
2 Cipla Limited AMPSolar Power Systems Private Limited Associate Any other transaction Electricity charges paid 200000000 Approved 80800000 0 0
3 Cipla Limited Aspergen Inc. Holding-Subsidiary Sale of goods or services 350000000 Approved 18400000 0 0
4 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 10000000 Approved 1300000 0 0
5 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 1600000 0 0
6 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Sale of goods or services 3210000000 Approved 874800000 0 0
7 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 50000000 Approved 200000 0 0
8 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Investment 8601400000 Approved 264400000 0 0
9 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Purchase of goods or services 250000000 Approved 15300000 0 0
10 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Sale of goods or services 2930000000 Approved 738900000 0 0
11 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 200000000 Approved 26200000 0 0
12 Cipla Limited Cipla Australia Pty. Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 100000000 Approved 42900000 0 0
13 Cipla Limited Cipla Australia Pty. Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 500000 0 0
14 Cipla Limited Cipla Australia Pty. Ltd. Holding-Subsidiary Purchase of goods or services 300000000 Approved 18300000 0 0
15 Cipla Limited Cipla Australia Pty. Ltd. Holding-Subsidiary Sale of goods or services 910000000 Approved 165800000 0 0
16 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Reimbursement Charges Paid 600000000 Approved 230400000 0 0
17 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Sale of goods or services 600000000 Approved 29200000 0 0
18 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 60000000 Approved 15000000 0 0
19 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Purchase of goods or services 240000000 Approved 39600000 0 0
20 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 500000 0 0
21 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Sale of goods or services 700000000 Approved 125500000 0 0
22 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 15000000 Approved 1000000 0 0
23 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Royalty Income 1100000 Approved 0 0 0
24 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Sale of goods or services 30000000 Approved 9700000 0 0
25 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Paid 350000000 Approved 168700000 0 0
26 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Received 16500000 Approved 800000 0 0
27 Cipla Limited Cipla Europe NV Holding-Subsidiary Sale of goods or services 3310000000 Approved 694000000 0 0
28 Cipla Limited Cipla Foundation The entity over which KMP or relative of KMP are able to exercise significant influence Any other transaction Donation Paid 1100000000 Approved 356200000 0 0
29 Cipla Limited Cipla Gulf FZ-LLC Holding-Subsidiary Any other transaction Reimbursement Charges Paid 150000000 Approved 19700000 0 0
30 Cipla Limited Cipla Gulf FZ-LLC Holding-Subsidiary Any other transaction Reimbursement Charges Received 150000000 Approved 200000 0 0
31 Cipla Limited Cipla Gulf FZ-LLC Holding-Subsidiary Sale of goods or services 2526300000 Approved 177700000 0 0
32 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 400000000 Approved 1800000 0 0
33 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Technical Know-How/Fees received 50000000 Approved 300000 0 0
34 Cipla Limited Cipla Health Limited Holding-Subsidiary Purchase of goods or services 1650000000 Approved 265600000 0 0
35 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Royalty Income 302500000 Approved 111200000 0 0
36 Cipla Limited Cipla Health Limited Holding-Subsidiary Sale of goods or services 1090000000 Approved 406600000 0 0
37 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Reimbursement Charges Received 22000000 Approved 200000 0 0
38 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Purchase of goods or services 154000000 Approved 39000000 0 0
39 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Sale of goods or services 10000000 Approved 200000 0 0
40 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 10000000 Approved 1100000 0 0
41 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved -700000 0 0
42 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Sale of goods or services 460000000 Approved 218200000 0 0
43 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund 1500000000 Approved 290000000 0 0
44 Cipla Limited Cipla Limited Employees Provident fund Post Employment Benefit Trust Any other transaction Contribution to Provident Fund 1600000000 Approved 281900000 0 0
45 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 600000 0 0
46 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Purchase of goods or services 150000000 Approved 40300000 0 0
47 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Sale of goods or services 10000000 Approved 0 0 0
48 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Reimbursement Charges Received 20000000 Approved 1100000 0 0
49 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Royalty Income 3000000 Approved 200000 0 0
50 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Sale of goods or services 1150000000 Approved 243600000 0 0
51 Cipla Limited Cipla Medpro Manufacturing (Pty) Limited Holding-Subsidiary Sale of goods or services 530000000 Approved -3300000 0 0
52 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 30000000 Approved 100000 0 0
53 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Interest received 0 Not Applicable 438300000 0 0
54 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Any other transaction Royalty Income 800000000 Approved 257800000 0 0
55 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Loan repaid 0 Not Applicable 790000000 0 0
56 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 300000000 Approved 34900000 0 0
57 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Interest received 0 Not Applicable 13200000 0 0
58 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Purchase of goods or services 500000000 Approved 80100000 0 0
59 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Rent received 30000000 Approved 6700000 0 0
60 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Royalty Income 500000000 Approved 165100000 0 0
61 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Sale of goods or services 7700000000 Approved 1929900000 0 0
62 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 120000000 Approved 700000 0 0
63 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Investment 3420000000 Approved 1626300000 0 0
64 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Rent paid 70000000 Approved 1600000 0 0
65 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Rent received 80000000 Approved 0 0 0
66 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Sale of goods or services 500000000 Approved 700000 0 0
67 Cipla Limited Cipla Select (Pty) Limited Holding-Subsidiary Sale of goods or services 1010000000 Approved 176700000 0 0
68 Cipla Limited Cipla Therapeutics Inc. Holding-Subsidiary Sale of goods or services 10000000 Approved 900000 0 0
69 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Loan repaid 0 Not Applicable 6243700000 0 0
70 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 4750000000 Approved 1243500000 0 0
71 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 200000000 Approved 1900000 0 0
72 Cipla Limited Cipla USA Inc. Holding-Subsidiary Interest received 0 Not Applicable 208500000 0 0
73 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Royalty Income 25000000000 Approved 10319400000 0 0
74 Cipla Limited Cipla USA Inc. Holding-Subsidiary Sale of goods or services 60550000000 Approved 12007300000 0 0
75 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Electricity charges paid 110000000 Approved 41100000 0 0
76 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Sale of goods or services 500000000 Approved 133000000 0 0
77 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 150000000 Approved 50700000 0 0
78 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 300000 0 0
79 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 1220000000 Approved 116900000 0 0
80 Cipla Limited GoApptiv Private Limited Associate Purchase of goods or services 650000000 Approved 152000000 0 0
81 Cipla Limited GoApptiv Private Limited Associate Sale of goods or services 120000000 Approved 600000 0 0
82 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Processing charges paid 1000000000 Approved 245400000 0 0
83 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 150000000 Approved 51800000 0 0
84 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 100000000 Approved 3000000 0 0
85 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Purchase of fixed assets 250000000 Approved 0 0 0
86 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Purchase of goods or services 2800000000 Approved 627400000 0 0
87 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of goods or services 1800000000 Approved 93300000 0 0
88 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Purchase of goods or services 2000000000 Approved 665000000 0 0
89 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of fixed assets 600000000 Approved 64900000 0 0
90 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of goods or services 10000000 Approved 2100000 0 0
91 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 200000000 Approved 7600000 0 0
92 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Purchase of goods or services 30000000 Approved 17500000 0 0
93 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Purchase of goods or services 500000000 Approved 124300000 0 0
94 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 2450000000 Approved 18000000 0 0
95 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges paid 900000000 Approved 303800000 0 0
96 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges received 150000000 Approved 10400000 0 0
97 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 100000000 Approved 1100000 0 0
98 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 20000000 Approved 8600000 0 0
99 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Purchase of goods or services 3850000000 Approved 1429100000 0 0
100 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of fixed assets 250000000 Approved 500000 0 0
101 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of goods or services 850000000 Approved 259000000 0 0
102 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Processing charges paid 700000000 Approved 151500000 0 0
103 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 50000000 Approved 1800000 0 0
104 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Purchase of goods or services 500000000 Approved 4600000 0 0
105 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Sale of goods or services 500000000 Approved 3200000 0 0
106 Cipla Limited Medpro Pharamaceutica (Pty) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 10000000 Approved -400000 0 0
107 Cipla Limited Medpro Pharamaceutica (Pty) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 70000000 Approved 27000000 0 0
108 Cipla Limited Medpro Pharamaceutica (Pty) Limited Holding-Subsidiary Sale of goods or services 6800000000 Approved 3211200000 0 0
109 Cipla Limited Mirren (Pty) Ltd Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 0 0 0
110 Cipla Limited Mirren (Pty) Ltd Holding-Subsidiary Sale of goods or services 20000000 Approved -1100000 0 0
111 Cipla Limited Sekhmet Technologies Private Limited Company in which a director or manager or his relative is a member or director Purchase of goods or services 150000000 Approved 4100000 0 0
112 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 50000000 Approved 12300000 0 0
113 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 100000000 Approved 7200000 0 0
114 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Testing and Analysis ChargesnPaid 1500000000 Approved 694200000 0 0
115 Cipla Limited Sitec Labs Limited Holding-Subsidiary Interest received 0 Not Applicable 7800000 0 0
116 Cipla Limited Sitec Labs Limited Holding-Subsidiary Loan 450000000 Approved 80000000 0 0
117 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of fixed assets 100000000 Approved 9000000 0 0
118 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of goods or services 40000000 Approved 10600000 0 0
119 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Reimbursement Charges Paid 10000000 Approved 3800000 0 0
120 Cipla Limited Stempeutics Research Private Limited Associate Purchase of goods or services 195000000 Approved 33400000 0 0
121 Cipla Limited Cipla USA Inc. Holding-Subsidiary Loan 13079000000 Approved 3923700000 0 0
122 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 50000000 Approved 4100000 0 0
123 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 50000000 Approved 5800000 0 0
124 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Purchase of fixed assets 250000000 Approved 800000 0 0
125 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Purchase of goods or services 200000000 Approved 116700000 0 0
126 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 10000000 Approved 6000000 0 0
127 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Purchase of goods or services 800000000 Approved 57700000 0 0
128 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Sale of goods or services 10000000 Approved 2200000 0 0
129 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of fixed assets 250000000 Approved 81300000 0 0
130 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 400000000 Approved 120000000 0 0
131 Cipla Limited Stempeutics Research Private Limited Associate Purchase of fixed assets 60000000 Approved 60000000 0 0
132 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 450000000 Approved 6800000 0 0
133 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Purchase of goods or services 400000000 Approved 143200000 0 0
134 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Investment 250000000 Approved 80000000 0 0
135 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Any other transaction Loan repaid 0 Not Applicable 3783200000 0 0
136 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Investment 4261600000 Approved 4261600000 0 0
137 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Sale of fixed assets 250000000 Approved 6600000 0 0
138 Cipla Limited Cipla Medpro Manufacturing (Pty) Limited Holding-Subsidiary Sale of fixed assets 70000000 Approved 11600000 0 0
139 Cipla Limited Mexicip S.A. de C.V Holding-Subsidiary Any other transaction Reimbursement Charges Paid 80000000 Approved 56700000 0 0
140 Cipla Limited Kemwell Biopharma Private Limited Private Companies in which a director or manager or his relative is a member or director Any other transaction Testing and Analysis ChargesnPaid 100000000 Approved 10300000 0 0
141 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 246700000 182400000
142 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 40100000 26600000
143 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 150100000 352600000
144 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 205200000 142600000
145 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 81400000 49000000
146 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Loan 0 Not Applicable 0 10253300000 5649000000 Loan 0 0 Unsecured Working Capital and capital expenditure Textual Information(1)
147 Cipla Limited Medpro Pharamaceutica (Pty) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 2634600000 3042800000
148 Cipla Limited Cipla Select (Pty) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 270300000 292400000
149 Cipla Limited Mirren (Pty) Ltd Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 22900000 14600000
150 Cipla Limited Cipla Medpro Manufacturing (Pty) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 57700000 49900000
151 Cipla Limited Cipla Medpro South African(Pty) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 188200000 235900000
152 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 159200000 168900000
153 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 167600000 411500000
154 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 209600000 175600000
155 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 30000000 33700000
156 Cipla Limited Cipla Australia Pty. Ltd. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 -141800000 43400000
157 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 80900000 6700000
158 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 714500000 489500000
159 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 92000000 88200000
160 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 109400000 107800000
161 Cipla Limited Sitec Labs Limited Holding-Subsidiary Loan 0 Not Applicable 0 180000000 260000000 Loan 0 5 Unsecured Working Capital Textual Information(2)
162 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Loan 0 Not Applicable 0 790000000 0 Loan 0.075 0 Unsecured Working Capital Textual Information(3)
163 Cipla Limited Cipla USA Inc. Holding-Subsidiary Loan 0 Not Applicable 0 8368600000 6011500000 Loan 0 2 Unsecured Working Capital Textual Information(4)
164 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 -9300000 2800000
165 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 -37100000 106200000
166 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 722000000 502500000
167 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 1649900000 676100000
168 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 8148900000 14345900000
169 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 387400000 321800000
170 Cipla Limited Cipla Therapeutics Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 0 200000
171 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 21800000 48000000
172 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 392500000 544100000
173 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 83300000 145100000
174 Cipla Limited Cipla Gulf FZ-LLC Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 207800000 46700000
175 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 2100000 28300000
176 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 631000000 588500000
177 Cipla Limited Mexicip S.A. de C.V Holding-Subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 0 56600000
178 Cipla Limited GoApptiv Private Limited Associate Any other transaction Trade and Other payable 0 Not applicable 0 45500000 78900000
179 Cipla Limited Sekhmet Technologies Private Limited Company in which a director or manager or his relative is a member or director Any other transaction Trade and Other payable 0 Not applicable 0 11000000 2100000
180 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Trade and Other payable 0 Not applicable 0 9800000 11500000
181 Cipla Limited AMP Energy Green Eleven Private Limited Associate Any other transaction Trade and Other payable 0 Not applicable 0 4000000 17200000
182 Cipla Limited Cipla Foundation The entity over which KMP or relative of KMP are able to exercise significant influence Any other transaction Trade and Other receivable 0 Not applicable 0 0 3300000
183 Cipla Limited AMPSolar Power Systems Private Limited Associate Any other transaction Trade and Other payable 0 Not applicable 0 800000 1700000
184 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Any other transaction Trade and Other receivable 0 Not applicable 0 151800000 133100000
185 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Trade and Other payable 0 Not applicable 0 4400000 1100000
186 Cipla Limited A S Kumar Director of subsidiary Any other transaction Trade and Other payable 0 Not applicable 0 6800000 10900000
187 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Any other transaction Trade and Other payable 0 Not applicable 0 2500000 6800000
188 Cipla Limited Achira Labs Private Limited Associate Any other transaction Trade and Other receivable 0 Not applicable 0 300000 300000
189 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Trade and Other receivable 0 Not applicable 0 98100000 63700000
190 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Capital Advances 0 Not Applicable 0 557400000 557400000
191 Cipla Limited M K HAMIED Non-executive Vice-Chairman Any other transaction Commission and Other Benefits payable 0 Not applicable 0 12500000 8900000
192 Cipla Limited Y K HAMIED Non-executive Chairman Any other transaction Commission and Other Benefits payable 0 Not applicable 0 12500000 15300000
193 Cipla Limited Samina Hamied Non-executive Director Any other transaction Commission and Other Benefits payable 0 Not applicable 0 12500000 8900000
194 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Commission and Other Benefits payable 0 Not applicable 0 0 6300000
195 Cipla Limited Kemwell Biopharma Private Limited Private Companies in which a director or manager or his relative is a member or director Any other transaction Trade and Other payable 0 Not applicable 0 0 9300000
196 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 117100000 98200000
197 Cipla Limited Cipla Limited Employees Provident fund Post Employment Benefit Trust Any other transaction Payable to Provident Fund Trust 0 Not Applicable 0 154600000 156400000
198 Cipla Limited A S Kumar Director of subsidiary Any other transaction Professional Fees 14800000 Approved 14800000 0 0
199 Cipla Limited Geena Malhotra Director of subsidiary Any other transaction Professional Fees 16300000 Approved 16300000 0 0
200 Cipla Limited Geena Malhotra Director of subsidiary Any other transaction Trade and Other payable 0 Not Applicable 0 0 1600000
201 Cipla Limited M K HAMIED Non-executive Vice-Chairman Any other transaction Sitting Fees/Commission and Other Benefits 2100000 Approved 2100000 0 0
202 Cipla Limited Y K HAMIED Non-executive Chairman Any other transaction Sitting Fees/Commission and Other Benefits 12900000 Approved 12900000 0 0
203 Cipla Limited Samina Hamied Non-executive Director Any other transaction Sitting Fees/Commission and Other Benefits 2200000 Approved 2200000 0 0
204 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Sitting Fees/Commission and Other Benefits 10700000 Approved 10700000 0 0
205 Aspergen Inc. Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 10000000 Approved 300000 0 0
206 Aspergen Inc. Kemwell Biopharma UK Limited Related party of the Subsidiary Any other transaction Equity infusion received 0 Not Applicable 171100000 0 0
207 Aspergen Inc. Cipla (EU) Limited Subsidiaries Any other transaction Capital Infusion received 0 Not Applicable 256600000 0 0
208 Aspergen Inc. Kemwell Biopharma Private Limited Related party of the Subsidiary Any other transaction Purchase of goods or services 1250000000 Approved 345900000 0 0
209 Cipla (EU) Limited Cipla Europe NV Subsidiaries Sale of goods or services 220000000 Approved 18900000 0 0
210 Cipla (EU) Limited Cipla Europe NV Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 19700000 0 0
211 Cipla (EU) Limited Cipla Gulf FZ – LLC Subsidiaries Interest received 4700000 Approved 4700000 0 0
212 Cipla (EU) Limited Cipla Australia Pty. Ltd. Subsidiaries Interest received 4100000 Approved 4100000 0 0
213 Cipla (EU) Limited Jiangsu Xidi Pharmaceutical Co. Ltd Related party of the Subsidiary Any other transaction Call Option excersied 470100000 Approved 431000000 0 0
214 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Interest received 38800000 Approved 38800000 0 0
215 Cipla (EU) Limited Mexicip S.A. de C.V. Subsidiaries Interest received 900000 Approved 900000 0 0
216 Cipla Health Limited Postcard Media LLP The entity over which KMP or relative of KMP are able ton exercise significant influence Any other transaction Trade and Other Payables 0 Not Applicable 0 100000 0
217 Cipla (EU) Limited Mexicip S.A. de C.V. Subsidiaries Any other transaction Loan Given 128200000 Approved 55600000 0 0
218 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Sale of goods or services 500000000 Approved 78800000 0 0
219 Goldencross Pharma Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 1500000 0 0
220 Goldencross Pharma Limited Goldencross Pharma Ltd Employees Group Gratuity Fund Post employment benefit trust Any other transaction Withdrawal from Trust 0 Not Applicable 2300000 0 0
221 Cipla (Jiangsu) Pharmaceutical Co. Limited Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 1250000000 Approved 1163100000 0 0
222 Jay Precision Pharmaceuticals Private Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 5000000 0 0
223 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Any other transaction Purchase of capital goods 200000000 Approved 53700000 0 0
224 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Any other transaction Rent Received 10000000 Approved 800000 0 0
225 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Sale of goods or services 10000000 Approved 400000 0 0
226 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Purchase of goods or services 10000000 Approved 1000000 0 0
227 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Sale of goods or services 250000000 Approved 33900000 0 0
228 Jay Precision Pharmaceuticals Private Limited Jay Precision Pharmaceuticals Employees Group Gratuity Trust Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0 Not Applicable 2400000 0 0
229 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Testing and Analysis Charges Received 50000000 Approved 600000 0 0
230 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 50000000 Approved 600000 0 0
231 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 50000000 Approved 0 0 0
232 Sitec Labs Limited InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Testing and Analysis Charges Received 100000000 Approved 900000 0 0
233 Sitec Labs Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 1800000 0 0
234 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Trust 0 Not Applicable 5900000 0 0
235 Cipla Therapeutics Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Capital Infusion received 128300000 Approved 128300000 0 0
236 Medispray Laboratories Private Limited Cipla Maroc S.A. Subsidiaries Sale of goods or services 330000000 Approved 129300000 0 0
237 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Sale of goods or services 350000000 Approved 100000 0 0
238 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Any other transaction Reimbursement charges received 20000000 Approved 800000 0 0
239 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Purchase of goods or services 50000000 Approved 400000 0 0
240 Medispray Laboratories Private Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 30000000 Approved 8700000 0 0
241 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Trust 0 Not Applicable 2200000 0 0
242 Meditab Specialities Limited Medispray Laboratories Private Limited Subsidiaries Sale of fixed assets 250000000 Approved 500000 0 0
243 Meditab Specialities Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 800000 0 0
244 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Trust 0 Not Applicable 100000 0 0
245 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate Any other transaction Service Charges Paid 10000000 Approved 2300000 0 0
246 Cipla Pharma and Life Sciences Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 3200000 0 0
247 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0 Not Applicable 14400000 0 0
248 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 1400000000 Approved 37400000 0 0
249 Cipla USA Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 200000000 Approved 1200000 0 0
250 Cipla USA Inc. Aspergen Inc. Subsidiaries Sale of goods or services 350000000 Approved 1300000 0 0
251 Cipla USA Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Reimbursement charges received 50000000 Approved 2300000 0 0
252 Cipla Gulf FZ – LLC Cipla Australia Pty. Ltd. Subsidiaries Any other transaction Reimbursement charges received 80000000 Approved 46100000 0 0
253 Cipla Gulf FZ – LLC Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Sale of goods or services 750000000 Approved 15600000 0 0
254 Exelan Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 10000000 Approved 2500000 0 0
255 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Sale of goods or services 185000000 Approved 30400000 0 0
256 Cipla Holding B.V. Cipla Europe NV Subsidiaries Sale of goods or services 110000000 Approved 20800000 0 0
257 Cipla Health Limited Boston Ivy Healthcare Solutions Private Limited (Medikabazaar) Company in which a director or manager or his relative is a member or director Sale of goods or services 10000000 Approved 1300000 0 0
258 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 30200000 0 0
259 Cipla Health Limited Cipla Foundation The entity over which KMP ornrelative of KMP are able tonexercise significant influence Any other transaction CSR Contribution 0 Not Applicable 4200000 0 0
260 Cipla Health Limited Samina Hamied Director of subsidiary Any other transaction Sitting Fees/Commission and Other Benefits 0 Not Applicable 100000 0 0
261 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Reimbursement charges paid 50000000 Approved 0 0 0
262 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 1750000000 Approved 826900000 0 0
263 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 11000000000 Approved 1334300000 0 0
264 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 34500000 0 0
265 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 1501900000 0 0
266 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Sale of goods or services 11000000000 Approved 1196200000 0 0
267 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 184700000 0 0
268 Cipla Australia Pty. Ltd. Cipla (EU) Limited Subsidiaries Any other transaction Loan Repaid 109400000 Approved 109400000 0 0
269 Cipla Europe NV Cipla (EU) Limited Subsidiaries Any other transaction Reimbursement charges received 0 Not Applicable 4200000 0 0
270 Cipla (China) Pharmaceutical Co., Ltd Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Any other transaction Reimbursement charges received 150000000 Approved 10100000 0 0
271 Cipla (China) Pharmaceutical Co., Ltd Shanghai Sage Business Consulting Co., Related party of the Subsidiary Any other transaction Professional Fees 40000000 Approved 13700000 0 0
272 Actor Pharma (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Royalty Income 50000000 Approved 12700000 0 0
273 Actor Pharma (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Royalty Income 40000000 Approved 6400000 0 0
274 Actor Pharma (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 1580000000 Approved 319700000 0 0
275 Actor Pharma (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Sale of goods or services 120000000 Approved 23900000 0 0
276 Cipla Empowerment Trust The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Distribution 40000000 Approved 2300000 0 0
277 Cipla-Medpro Distribution Centre (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Distribution fee income 1000000000 Approved 375700000 0 0
278 Cipla Medpro Manufacturing (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 5000000000 Approved 1845700000 0 0
279 Cipla Medpro Manufacturing (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Sale of goods or services 150000000 Approved 14000000 0 0
280 Cipla Medpro Manufacturing (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Donation paid 150000000 Approved 400000 0 0
281 Cipla Medpro South Africa (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 200000000 Approved 6300000 0 0
282 Cipla Medpro South Africa (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Royalty Income 400000000 Approved 213000000 0 0
283 Cipla Medpro South Africa (Pty) Limited Brandmed (Pty) Limited Associate Interest received 9800000 Approved 9800000 0 0
284 Cipla Select (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 10000000 Approved 2600000 0 0
285 Cipla-Medpro (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Royalty Income 300000000 Approved 104300000 0 0
286 Cipla-Medpro (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Royalty Income 60000000 Approved 6500000 0 0
287 Medpro Pharmaceutica (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Sale of goods or services 300000000 Approved 33700000 0 0
288 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro Distribution Centre (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 120000000 Approved 87600000 0 0
289 Medpro Pharmaceutica (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Reimbursement charges received 200000000 Approved 2700000 0 0
290 Medpro Pharmaceutica (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction CSR Contribution 100000000 Approved 46700000 0 0
291 Medpro Pharmaceutica (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 60000000 Approved 18000000 0 0
292 Cipla Medpro South Africa (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Interest Received -33700000 Approved -33700000 0 0
293 Medpro Pharmaceutica (Pty) Limited Cipla Medpro South Africa (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 900000000 Approved 83200000 0 0
294 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Reimbursement charges paid 800000000 Approved 663600000 0 0
295 Medpro Pharmaceutica (Pty) Limited Mirren (Pty) Ltd Subsidiaries Any other transaction Reimbursement charges received 80000000 Approved 1500000 0 0
296 Medpro Pharmaceutica (Pty) Limited Cipla Kenya Limited Subsidiaries Any other transaction Reimbursement charges received 50000000 Approved 500000 0 0
297 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro (Pty) Limited Subsidiaries Any other transaction Recovery of annual license fees/dossiers 500000000 Approved 24900000 0 0
298 Mirren (Pty) Ltd Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 1500000000 Approved 486700000 0 0
299 Cipla Maroc S.A. Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of the Subsidiary Purchase of goods or services 150000000 Approved 50100000 0 0
300 Cipla Maroc S.A. Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of the Subsidiary Sale of goods or services 2320000000 Approved 1332000000 0 0
301 Cipla Medpro South Africa (Pty) Limited Medpro Pharmaceutica Proprietary Ltd. Subsidiaries Any other transaction Conversion of loan into equity investment 4236800000 Approved 4229200000 0 0
302 Meditab Holdings Limited Cipla Kenya Limited Subsidiaries Interest received 10700000 Approved 10700000 0 0
303 Cipla (EU) Limited MKC Biotherapeutics Associate Investment 145300000 Approved 50100000 0 0
304 Aspergen Inc. Kemwell Biopharma Private Limited Related party of the Subsidiary Any other transaction Trade and Other Payables 0 Not Applicable 0 82300000 281000000
305 Cipla Australia Pty. Ltd. Cipla Gulf FZ-LLC Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 46200000 88900000
306 Cipla (China) Pharmaceutical Co., Ltd Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 5700000 5200000
307 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 10000000 33100000
308 Cipla Health Limited Cipla Health Limited Employees Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 31300000 800000
309 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate Any other transaction Trade and other Receivable 0 Not Applicable 0 1200000 1200000
310 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 2800000 17200000
311 Cipla (EU) Limited Cipla Europe NV Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 152600000 219400000
312 Cipla (EU) Limited Cipla Gulf FZ-LLC Subsidiaries Loan 0 Not Applicable 0 167600000 171000000 Loan 0.055 3 Unsecured Business Purpose
313 Cipla (EU) Limited Cipla Australia Pty. Ltd. Subsidiaries Any other transaction Interest receivable 0 Not Applicable 0 23100000 2900000
314 Cipla (EU) Limited Cipla Australia Pty. Ltd. Subsidiaries Loan 0 Not Applicable 0 380900000 245700000 Loan 0.028 4 Unsecured Business Purpose
315 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Loan 0 Not Applicable 0 1391000000 1418900000 Loan 0 1 Unsecured Working capital Textual Information(5)
316 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Any other transaction Interest receivable 0 Not Applicable 0 111300000 152200000
317 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Freight charges received 10000000 Approved 0 0 0
318 Cipla (EU) Limited Mexicip S.A. de C.V. Subsidiaries Loan 0 Not Applicable 0 0 55600000 Loan 0.08 2 Unsecured Working capital
319 Exelan Pharmaceuticals Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 874700000
320 Exelan Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 2500000
321 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 13400000 9600000
322 Goldencross Pharma Limited Goldencross Pharma Ltd Employees Group Gratuity Fund Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 27700000 29900000
323 Cipla Gulf FZ – LLC Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 34600000 50800000
324 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 129500000 132300000
325 Cipla Holding B.V. Cipla Europe NV Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 71900000 91800000
326 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 1379200000 0
327 Cipla (Jiangsu) Pharmaceutical Co. Limited Cipla (EU) Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 2200000 2200000
328 Cipla (Jiangsu) Pharmaceutical Co. Limited Cipla USA Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 676900000
329 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Any other transaction Capital advances payable 0 Not Applicable 0 38200000 58500000
330 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Any other transaction Trade and other Receivable 0 Not Applicable 0 3000000 3300000
331 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 16300000 10800000
332 Jay Precision Pharmaceuticals Private Limited Jay Precision Pharmaceuticals Employees Group Gratuity Trust Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 1300000 800000
333 Medispray Laboratories Private Limited Cipla Maroc S.A. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 112500000 129700000
334 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related party of the Subsidiary Any other transaction Advance given 0 Not Applicable 0 0 35100000
335 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 83300000 93900000
336 Meditab Specialities Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 400000 300000
337 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 10800000 20700000
338 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 200000 300000
339 Sitec Labs Limited Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 1700000 0
340 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 200000 800000
341 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 0
342 Sitec Labs Limited Cipla Health Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 0
343 Sitec Labs Limited InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 4600000 2700000
344 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0 Not Applicable 0 52400000 57900000
345 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 3453700000 936700000
346 Cipla USA Inc. Aspergen Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 30400000 6800000
347 Cipla USA Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 0 2300000
348 Cipla USA Inc. Cipla (Jiangsu) Pharmaceutical Co. Limited Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 544700000 0
349 Actor Pharma (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 328800000 253900000
350 Actor Pharma (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 45200000 143300000
351 Cipla-Medpro Distribution Centre (Pty) Limited Cipla Kenya Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 2600000 2500000
352 Cipla Medpro Manufacturing (Pty) Limited Cipla Empowerment Trust Entities over which the company is able to exercise significant influence/Control Loan 0 Not Applicable 0 0 0
353 Cipla Medpro South Africa (Pty) Limited Brandmed (Pty) Limited Associate Loan 0 Not Applicable 0 198900000 201600000 Loan 0 0 Unsecured Working Capital Textual Information(6)
354 Cipla Medpro South Africa (Pty) Limited Cipla-Medpro (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 21000000 20200000
355 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 781900000 3118900000
356 Cipla Kenya Limited Meditab Holdings Limited Subsidiaries Loan 0 Not Applicable 0 210000000 227100000 Loan 0.06 0 Unsecured Working Capital Textual Information(7)
357 Cipla Medpro South Africa (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 158600000 402100000
358 Cipla Medpro South Africa (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Loan 0 Not Applicable 0 8432600000 3671900000 Loan 0 0 Unsecured Working Capital Textual Information(8)
359 Cipla Select (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 17100000 2000000
360 Cipla-Medpro (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 45700000 51500000
361 Medpro Pharmaceutica (Pty) Limited Cipla Medpro South Africa (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 1981400000 3306600000
362 Medpro Pharmaceutica (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 76400000 4200000
363 Medpro Pharmaceutica (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Trade and Other Payables 0 Not Applicable 0 -6500000 162200000
364 Medpro Pharmaceutica (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Trade and Other receivable 0 Not Applicable 0 3800000 6400000
365 Medpro Pharmaceutica (Pty) Limited Cipla Kenya Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 272200000 261900000
366 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro Distribution Centre (Pty) Limited Subsidiaries Any other transaction Trade and Other Payables 0 Not Applicable 0 67900000 96800000
367 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 72400000 1300000
368 Medpro Pharmaceutica (Pty) Limited Mirren (Pty) Ltd Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 537100000 519400000
369 Mirren (Pty) Ltd Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 100000000 189000000
370 Cipla Medpro Manufacturing (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 2091500000 2877800000
371 Cipla Medpro Manufacturing (Pty) Limited Cipla Select (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 64500000 72100000
372 Cipla Medpro Botswana (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other receivable 0 Not Applicable 0 0 0
373 Cipla Maroc S.A. Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of the Subsidiary Any other transaction Interest Payable 0 Not Applicable 0 5700000 5900000
374 Cipla Maroc S.A. Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of the Subsidiary Any other transaction Trade and Other receivable 0 Not Applicable 0 448200000 443200000
375 Cipla Gulf FZ – LLC Cipla USA Inc. Subsidiaries Any other transaction Trade and other Receivable 0 Not Applicable 0 1100000 0
Total value of transaction during the reporting period 81521900000



Text Block
Textual Information(1) Interest Rate 250 bps higher than 3 months JIBAR rate capped at the prime lending rate in South Africa Tenure Repayment starts with 31st March 2026 to Oct 2029
Textual Information(2) Interest Rate 6.5 to 7.45 percent
Textual Information(3) Tenure Repaid during the year
Textual Information(4) Interest Rate Term SOFR 140 to 150 bps
Textual Information(5) Interest Rate 4 to 6 percent
Textual Information(6) Interest Rate South African prime rate less 1.75 percent Tenure Repayment to start from 31 March 2025 to 31 March 2028
Textual Information(7) Tenure Payable on Demand
Textual Information(8) Interest Rate 250 bps higher than 3 months JIBAR rate capped at the prime lending rate in South Africa Tenure Repayament starts with 31 March 2026 to Oct 2029


Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt